IRIS Accounts Production v25.1.0.734 03011929 Board of Directors 1.1.24 31.12.24 31.12.24 false true true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh030119292023-12-31030119292024-12-31030119292024-01-012024-12-31030119292022-12-31030119292023-01-012023-12-31030119292023-12-3103011929ns15:EnglandWales2024-01-012024-12-3103011929ns14:PoundSterling2024-01-012024-12-3103011929ns10:Director12024-01-012024-12-3103011929ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3103011929ns10:SmallEntities2024-01-012024-12-3103011929ns10:Audited2024-01-012024-12-3103011929ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-3103011929ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3103011929ns10:FullAccounts2024-01-012024-12-3103011929ns10:OrdinaryShareClass12024-01-012024-12-3103011929ns10:Director22024-01-012024-12-3103011929ns10:Director32024-01-012024-12-3103011929ns10:Director42024-01-012024-12-3103011929ns10:Director62024-01-012024-12-3103011929ns10:RegisteredOffice2024-01-012024-12-3103011929ns10:Director52024-01-012024-12-3103011929ns5:CurrentFinancialInstruments2024-12-3103011929ns5:CurrentFinancialInstruments2023-12-3103011929ns5:ShareCapital2024-12-3103011929ns5:ShareCapital2023-12-3103011929ns5:RetainedEarningsAccumulatedLosses2024-12-3103011929ns5:RetainedEarningsAccumulatedLosses2023-12-3103011929ns5:ShareCapital2022-12-3103011929ns5:RetainedEarningsAccumulatedLosses2022-12-3103011929ns5:RetainedEarningsAccumulatedLosses2023-01-012023-12-3103011929ns5:RetainedEarningsAccumulatedLosses2024-01-012024-12-3103011929ns5:OwnedAssets2024-01-012024-12-3103011929ns5:OwnedAssets2023-01-012023-12-3103011929ns10:OrdinaryShareClass12023-01-012023-12-3103011929ns5:PlantMachinery2023-12-3103011929ns5:PlantMachinery2024-01-012024-12-3103011929ns5:PlantMachinery2024-12-3103011929ns5:PlantMachinery2023-12-3103011929ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3103011929ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3103011929ns10:OrdinaryShareClass12024-12-31
REGISTERED NUMBER: 03011929 (England and Wales)














Report of the Directors and

Financial Statements

for the Year Ended 31st December 2024

for

Wolf Laboratories Limited

Wolf Laboratories Limited (Registered number: 03011929)






Contents of the Financial Statements
for the year ended 31st December 2024




Page

Company Information 1

Report of the Directors 2

Report of the Independent Auditors 4

Statement of Comprehensive Income 8

Balance Sheet 9

Statement of Changes in Equity 10

Notes to the Financial Statements 11


Wolf Laboratories Limited

Company Information
for the year ended 31st December 2024







DIRECTORS: N. A. Bewell
D. J. Child
J. A. Foss
D. A. Suddaby
I. A. Roulstone



REGISTERED OFFICE: Colenso House
1 Deans Lane
Pocklington
YO42 2PX



REGISTERED NUMBER: 03011929 (England and Wales)



AUDITORS: Sadofskys
Statutory Auditors
Princes House
Wright Street
Hull
East Yorkshire
HU2 8HX



BANKERS: Natwest Bank Plc
60-61 Saturday Market
Beverley
HU17 8AA

Wolf Laboratories Limited (Registered number: 03011929)

Report of the Directors
for the year ended 31st December 2024

The directors present their report with the financial statements of the company for the year ended 31st December 2024.

PRINCIPAL ACTIVITY
The principal activity of the company in the year under review was that of laboratory supplies.

DIRECTORS
The directors set out in the table below have held office during the whole of the period from 1st January 2024 to the date of this report unless otherwise stated.

Other changes in directors holding office are as follows:

S. A. Woodward - resigned 15/2/24

The directors shown below were in office at 31st December 2024 but did not hold any interest in the Ordinary shares of £1 each at 1st January 2024 or 31st December 2024.

N. A. Bewell
D. J. Child
J. A. Foss
D. A. Suddaby
I. A. Roulstone

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

-select suitable accounting policies and then apply them consistently;
-make judgements and accounting estimates that are reasonable and prudent;
-prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

AUDITORS
The auditors, Sadofskys, will be proposed for re-appointment at the forthcoming Annual General Meeting.


Wolf Laboratories Limited (Registered number: 03011929)

Report of the Directors
for the year ended 31st December 2024

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:





N. A. Bewell - Director


28th March 2025

Report of the Independent Auditors to the Members of
Wolf Laboratories Limited

Opinion
We have audited the financial statements of Wolf Laboratories Limited (the 'company') for the year ended 31st December 2024 which comprise the Statement of Comprehensive Income, Balance Sheet, Statement of Changes in Equity and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the company's affairs as at 31st December 2024 and of its profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Directors has been prepared in accordance with applicable legal requirements.

Report of the Independent Auditors to the Members of
Wolf Laboratories Limited


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemption from the requirement to prepare a Strategic Report or in preparing the Report of the Directors.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Members of
Wolf Laboratories Limited


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the company through discussions with directors and other management, and from our commercial knowledge and experience of the laboratory equipment and consumables sector;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the company, including the Companies Act 2006, UK tax legislation, and data protection, anti-bribery, employment, environmental and health and safety legislation;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:
- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:
- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;
- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:
- agreeing financial statement disclosures to underlying supporting documentation;
- reading the minutes of meetings of those charged with governance;
- enquiring of management as to actual and potential litigation and claims; and
- reviewing correspondence with HMRC, relevant regulators, and the company's legal advisors.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Report of the Independent Auditors to the Members of
Wolf Laboratories Limited


Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Alan Brocklehurst (Senior Statutory Auditor)
for and on behalf of Sadofskys
Statutory Auditors
Princes House
Wright Street
Hull
East Yorkshire
HU2 8HX

28th March 2025

Wolf Laboratories Limited (Registered number: 03011929)

Statement of Comprehensive
Income
for the year ended 31st December 2024

2024 2023
Notes £    £   

TURNOVER 17,515,568 14,367,009

Cost of sales 14,908,873 11,827,196
GROSS PROFIT 2,606,695 2,539,813

Administrative expenses 1,553,790 1,484,333
1,052,905 1,055,480

Other operating income 11,637 13,115
OPERATING PROFIT 4 1,064,542 1,068,595

Interest receivable and similar income 37,403 35,266
1,101,945 1,103,861

Interest payable and similar expenses 4,666 -
PROFIT BEFORE TAXATION 1,097,279 1,103,861

Tax on profit 5 278,157 260,617
PROFIT FOR THE FINANCIAL YEAR 819,122 843,244

OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME
FOR THE YEAR

819,122

843,244

Wolf Laboratories Limited (Registered number: 03011929)

Balance Sheet
31st December 2024

2024 2023
Notes £    £    £   
FIXED ASSETS
Tangible assets 7 146,675 108,986

CURRENT ASSETS
Stocks 390,134 236,775
Debtors 8 3,120,249 3,432,503
Cash at bank and in hand 1,320,052 2,447,659
4,830,435 6,116,937
CREDITORS
Amounts falling due within one year 9 2,623,520 3,951,176
NET CURRENT ASSETS 2,206,915 2,165,761
TOTAL ASSETS LESS CURRENT
LIABILITIES

2,353,590

2,274,747

PROVISIONS FOR LIABILITIES 35,794 26,073
NET ASSETS 2,317,796 2,248,674

CAPITAL AND RESERVES
Called up share capital 10 40,000 40,000
Retained earnings 2,277,796 2,208,674
SHAREHOLDERS' FUNDS 2,317,796 2,248,674

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Directors and authorised for issue on 28th March 2025 and were signed on its behalf by:





N. A. Bewell - Director


Wolf Laboratories Limited (Registered number: 03011929)

Statement of Changes in Equity
for the year ended 31st December 2024

Called up
share Retained Total
capital earnings equity
£    £    £   
Balance at 1st January 2023 40,000 1,365,430 1,405,430

Changes in equity
Total comprehensive income - 843,244 843,244
Balance at 31st December 2023 40,000 2,208,674 2,248,674

Changes in equity
Dividends - (750,000 ) (750,000 )
Total comprehensive income - 819,122 819,122
Balance at 31st December 2024 40,000 2,277,796 2,317,796

Wolf Laboratories Limited (Registered number: 03011929)

Notes to the Financial Statements
for the year ended 31st December 2024

1. STATUTORY INFORMATION

Wolf Laboratories Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Significant judgements and estimates
In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on the directors historical experience and knowledge as well as other factors which may be considered relevant, as a result the actual results may differ from these estimates.

The estimates and underlying assumptions applied are reviewed by the directors on an ongoing basis.

Revisions to these accounting estimates are recognised in the period to which the revisions have been revised where these revisions affect only that period, or in the period of revision and future period where this revision would affect both current and future periods.

No key sources of estimation uncertainty are noted by management that have a significant effect on the amounts recognised in the financial statements.

Revenue recognition
(i) Sale of goods and materials: Revenue for the sale of goods and materials is recognised when goods are delivered or used and legal title of the goods supplied has been passed to the customer, sales are made on a credit basis. The amounts reported are net of VAT and trade discounts.

(ii) Interest Income: Interest income is recognised using the effective interest rate method.

Wolf Laboratories Limited (Registered number: 03011929)

Notes to the Financial Statements - continued
for the year ended 31st December 2024

2. ACCOUNTING POLICIES - continued

Property, plant and equipment
Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses.

Depreciation is provided on all property, plant and equipment, at rates calculated to write off the cost less estimated residual value, of each item on a systematic basis over their expected useful lives as follows:

Plant and machinery etc - 25% on cost

Assets held under hire purchase agreements of finance leases are depreciated in the same way as owned assets.

At each balance sheet date, the company reviews the carrying amount of its tangible fixed assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss, if any. Where it is not possible to estimate the recoverable amount of the asset, the company estimates the recoverable amount of the cash-generating unit to which the assets belong.

Inventories
Inventories are stated at the lower of cost and estimated selling price less costs to sale. Inventories are recognised as an expenses in the period in which the related revenue is recognised.

Cost includes all costs of the purchases, costs of conversion and other costs incurred in bringing stock to its present location and condition. Provision is made for damaged, obsolete and slow moving stock where appropriate.

Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.

Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability.

Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.

Taxation
Taxation expenses for the year comprises current and deferred tax recognised in the reporting period. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax represents the amount of tax payable or receivable in respect of the taxable profit (or loss) for the current or past reporting periods. It is measured at the amount expected to be paid or recovered using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Wolf Laboratories Limited (Registered number: 03011929)

Notes to the Financial Statements - continued
for the year ended 31st December 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Transactions in currencies, other than the functional currency of the company, are recorded are the rate of exchange on the date the transaction occurs. Monetary items denominated in other currencies are translated the rate of exchange prevailing at the end of the reporting period. Exchange differences are taken into account in arriving at the operating result. Non-monetary items that are measured at historic cost in a foreign currency are not retranslated.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Short-term employee benefits are recognised as an expense on the period they are incurred.

The obligations for contributions to the defined contribution schemes are recognised as an expense in the period they are incurred. The assets of the schemes are held separately from those of the company in independently administered funds.

Debtors and creditors receivable/payable within one year
i) Trade and other debtors:

Short term trade and other debtors are initially measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transactions costs and are measured subsequently at amortised costs using the effective interest method, less any impairment.

ii) Trade and other creditors:

Short term trade and other creditors are initially measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 30 (2023 - 29 ) .

Wolf Laboratories Limited (Registered number: 03011929)

Notes to the Financial Statements - continued
for the year ended 31st December 2024

4. OPERATING PROFIT

The operating profit is stated after charging:

2024 2023
£    £   
Depreciation - owned assets 51,705 33,728
Auditors' remuneration 3,700 3,500

5. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
2024 2023
£    £   
Current tax:
UK corporation tax 264,898 254,577
Taxation in relation to prior
years 3,538 -
Total current tax 268,436 254,577

Deferred taxation 9,721 6,040
Tax on profit 278,157 260,617

6. DIVIDENDS
2024 2023
£    £   
Interim 750,000 -

7. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1st January 2024 231,234
Additions 89,394
Disposals (21,851 )
At 31st December 2024 298,777
DEPRECIATION
At 1st January 2024 122,248
Charge for year 51,705
Eliminated on disposal (21,851 )
At 31st December 2024 152,102
NET BOOK VALUE
At 31st December 2024 146,675
At 31st December 2023 108,986

Wolf Laboratories Limited (Registered number: 03011929)

Notes to the Financial Statements - continued
for the year ended 31st December 2024

8. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 2,280,975 1,013,220
Amounts owed by group undertakings 554,644 1,237,645
Taxation 19,102 -
Prepayments and accrued income 265,528 1,181,638
3,120,249 3,432,503

9. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 1,206,861 1,465,046
Taxation - 118,577
Social security and other taxes 92,051 71,546
Other creditors 429,962 464,945
Accruals and deferred income 894,646 1,831,062
2,623,520 3,951,176

10. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
40,000 Ordinary £1 40,000 40,000

11. ULTIMATE PARENT AND CONTROLLING PARTY

The ultimate controlling party is LBO France, a company registered in France (RCS Strasbourg Reg. No. 418354502). The immediate parent company is Flow Group Holdings Limited, a company registered in England and Wales (Reg. No. 11869393).

The parent of the largest group for which consolidated financial statements are drawn up is Dutscher Holding. Copies of the consolidated accounts can be obtained from 2C, Rue De Bruxelles, 67170, Bernolsheim, France.

The parent of the smallest group for which consolidated financial statements are drawn up is Scientific Laboratory Supplies Group Limited, whose registered office address is Orchard House, The Square, Hessle, United Kingdom, HU13 0AE.

Dutscher Holding SAS (incorporated in France) is regarded by the directors as being the company's ultimate parent company (RCS Strasbourg Reg. No. 882634660).